Single-cell Omics Market
Report ID: SQMIG35J2284
Report ID: SQMIG35J2284
[email protected]
USA +1 351-333-4748
Report ID:
SQMIG35J2284 |
Region:
Global |
Published Date: May, 2026
Pages:
157
|Tables:
119
|Figures:
77
Global Single-Cell Omics Market size was valued at USD 4.82 Billion in 2024 and is poised to grow from USD 5.61 Billion in 2025 to USD 18.85 Billion by 2033, growing at a CAGR of 16.32% during the forecast period (2026-2033).
Single-cell omics market trends have emerged as a high-resolution suite of technologies for profiling genomes, transcriptomes, epigenomes and proteomes at the level of the individual cell, largely driven by the need to uncover cellular heterogeneity that is obscured by bulk assays. Because understanding cell-to-cell variation transforms basic biology into actionable clinical insights, including studies of the tumor microenvironment that identify resistant clones and immune profiling that informs checkpoint inhibitor therapies. Development has advanced from early microfluidics and low-throughput plate-based assays to high-throughput droplet sequencing and multimodal platforms. Companies such as 10x Genomics and Mission Bio have commercialized workflows, lowering costs and speeding up adoption.
A major driver of growth is the plummeting costs per sample and per cell, which have driven up adoption in academia and industry as the low costs make both large cohorts and longitudinal studies feasible, and are drawing pharma investment. Thus, companies are engaging biopharma teams to apply single-cell profiling to target validation, patient stratification and monitoring of minimal residual disease, for example, immuno-oncology trials that use T cell clonality and expression signatures to predict response. The emergence of computational analytics and spatial omics has created opportunities for diagnostics and companion assays, with engagement from regulators and commercial pathways in clinical diagnostics and cell therapy quality control.
How is AI Accelerating Biomarker Discovery in the Single-cell Omics Market?
AI is accelerating biomarker discovery in the single-cell omics market growth by automating detection of subtle cellular signatures and by integrating diverse data types from RNA protein and spatial assays. Key components include scalable pattern recognition across large cell atlases and transfer learning for generalizing biomarkers across studies. What we are seeing now is rapid uptake by drug developers who need clearer target hypotheses and faster translational readouts. Examples include foundation models trained on multi-omics data and AI-driven clinical single-cell platforms that reduce experimental cycles and reveal rare cell states that are actionable biomarkers.
10x Genomics July 2025, announced TISHUMAP collaboration with A STAR Genome Institute to apply multimodal AI to spatial and histology data and to accelerate biomarker and target discovery through richer single cell signatures.
Market snapshot - (2026-2033)
Global Market Size
USD 4.82 Billion
Largest Segment
Single-Cell Transcriptomics (scRNA-seq)
Fastest Growth
Single-Cell Proteomics
Growth Rate
16.32% CAGR
To get more insights on this market click here to Request a Free Sample Report
Global single-cell omics market is segmented by technology, product, application, end-user and region. Based on technology, the market is segmented into single-cell genomics, single-cell transcriptomics (scRNA-seq), single-cell proteomics and single-cell epigenomics. Based on product, the market is segmented into instruments, reagents & kits and software & bioinformatics. Based on application, the market is segmented into oncology, immunology, neuroscience and developmental biology. Based on end-user, the market is segmented into research institutes, pharma & biotech and CROs. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.
The single-cell transcriptomics segment dominates as the widespread adoption of single-cell RNA sequencing has made it the primary discovery engine in single-cell omics. Mature protocols, the broad availability of reagents and platforms that can be integrated generate high resolution transcriptional maps that reveal cell states and disease mechanisms and drive biomarker and target nomination. This built infrastructure attracts continuous investment, generates common workflows across labs, and accelerates incorporation into translational programs and clinical research and translation.
However, single-cell proteomics is emerging as the fastest growing area, as advances in sensitivity and multiplexing are revealing protein level heterogeneity beyond transcripts. Better mass spectrometry workflows and targeted antibody panels in translational research and drug development are also pushing adoption, opening up new biomarker and target discovery paths that broaden single-cell omics use cases.
Software & bioinformatics segment is expected to be dominant during the forecast period as the strong analytic frameworks and integration tools are necessary for the conversion of complex single-cell output to actionable insights. Cross-platform harmonization, multi-omics integration, reproducible analyses and support for regulatory workflows are the basis for translational decision making and are facilitated by scalable pipelines, machine learning models and visualization suites. Commercial platforms and cloud-enabled services are lowering the barriers to implementation for labs and enterprises, encouraging partnerships and ongoing investment in computational solutions.
Reagents & kits, however, remains the fastest growing product area as standardized library preparation and barcoding chemistries lower technical barriers. Turnkey consumables automate processes and enable reproducible workflows, accelerating adoption across research and industry, driving recurring consumable revenue and expanding practical applications that foster sustained market growth.
To get detailed segments analysis, Request a Free Sample Report
North America is the leading region globally in the single-cell omics market, driven by a unique combination of high levels of research excellence, strong commercial ecosystems and advanced clinical translation pathways. Leading academic and medical centers drive methodological innovation while large biotech and instrument companies help to accelerate commercialization of platforms and consumables. Lucrative regulatory environments and well-formed venture capital networks enable rapid scaling of innovative technologies. High performance computing, extensive bioinformatics pipelines and multidisciplinary academia-industry collaborations enable value capture from complex datasets. Moreover, its widespread use by translational research programs and large clinical networks enables early validation of the applications in disease biology, drug discovery and precision medicine, reinforcing its market leadership and creating sustainable demand for next generation single-cell solutions. Strong partnerships with health care providers and investment in workforce training are the foundation for continued innovation and market resilience.
Single-cell omics market share in the United States is driven by the presence of leading research universities, advanced clinical centers and a concentration of instrument manufacturers and biotech firms. Strong collaborations between academia, industry and healthcare systems accelerate translational studies. Venture funding and pathways to commercialization are strong so startups can quickly scale technologies. Strong bioinformatics capabilities and wide adoption in translational research programs support refinement of single-cell workflows and drive continued market activity across areas.
Single-cell omics market outlook in Canada is bolstered by a culture of collaborative research, integrated health data initiatives, and emerging biotech clusters with an emphasis on translational science. Method validation and clinical studies are facilitated by strong links between the universities, research hospitals and local life science companies. National research programs and the focus on precision medicine are driving the adoption of single-cell platforms. Emphasis on inter-disciplinary training and partnerships with vendors enhances capacity for advanced omics applications. platforms. Focus on interdisciplinary training and partnerships with vendors strengthens capacity for advanced omics applications.
In Europe, the fast-growing single-cell omics landscape is supported by a rich ecosystem of academic excellence, strong industry engagement and coordinated research efforts that put a strong focus on translational outcomes. Large pharmaceutical and biotech players across the region are investing in single-cell technologies to enhance drug discovery and biomarker development, while national and cross-border collaborations are enabling the sharing of expertise and standardized workflows. The adoption in both research and clinical settings is enabled by the increasing focus on precision medicine and improvements in clinical infrastructure and bioinformatics capacity. Policy support for life science innovation and strategic public private partnerships enable bridging innovation to commercialization. Europe is thus a dynamic arena for methodological refinement and diversification of application in single cell omics. Growing demand for targeted therapies and established clinical trial networks are also fuelling market momentum across markets.
Single-cell omics market regional forecast in Germany is supported by the presence of research universities, translational centers, and a robust medtech manufacturing base that facilitates platform development. Collaboration between industry and clinical institutions speeds up validation of single-cell assays for translational and diagnostic applications. A focus on quality systems, technical workforce development and cross sector partnerships encourage scalable implementation. The demand for enhanced single-cell solutions in research and healthcare more generally is sustained by national programs for innovation and the active participation of clinicians.
Single-cell omics market regional outlook in United Kingdom the vibrant translational research environment, strong university medical centers and a startup ecosystem that accelerates commercialization support the single cell omics market. Greater collaboration between academia and pharmaceutical companies drives the adoption of single-cell workflows in drug discovery and biomarker programs. Validation supported by national health data initiatives and integrated clinical networks. Policy focus on the growth and investment climate for life sciences encourages innovation and market uptake across research areas and adoption.
Single-cell omics market forecast in France is taking off with strong public research institutions, translational centers and collaborative life science clusters bridging academia and industry . Clinical projects and collaborations with biotech companies stimulate the uptake of single-cell approaches. National innovation programs and the supporting policy frameworks trigger the development of diagnostic and therapeutic applications. Increased investment in bioinformatics and training increases capacity to deploy single cell workflows broadly across research and clinical validation initiatives.
Strategic investments in research infrastructure, expanding life science industrial capabilities and public private partnerships are strengthening Asia Pacific’s single cell omics industry position. National research institutions and major universities in key markets focus on single cell methods for applications from basic biology to translational studies. Domestic instrument manufacturers and reagent suppliers increase regional access to platforms. The integration of clinical cohorts with genomics initiatives and the focus on bioinformatics training enhances local capacity to interpret complex single-cell data. Cross-border partnerships with multinationals allow for technology transfer and local adaptation, and enable Asia Pacific centers to move from adoption to innovation in protocols, applications and specialized services that respond to regional disease priorities. Additional support for translation of single-cell discoveries into regionally relevant diagnostics and therapies comes from modernizing regulatory pathways and expanding clinical trial networks.
Single-cell omics market penetration in Japan is supported by advanced research institutions, strong pharmaceutical company engagement and instrument manufacturing expertise that enables access to high-quality platforms and reagents. Collaborative networks to support translational research and protocol optimization between universities, clinical centers and industry accelerate Improved interpretation of single-cell datasets by focusing on bioinformatics capacity building and integration of clinical cohorts. Strategic efforts to link basic science and application development advance local innovation and service delivery.
Single-cell omics trends in South Korea is being driven by focused government support for biotechnology, leading university research programs and a commercial ecosystem of innovative startups and research providers. Linking national genomics initiatives to clinical networks enables applied single cell research and validation. Domestic companies improve supply chain capabilities and investments in bioinformatics and workforce training develop analytical capacity. Cross sector collaboration with multinational partners improves technological adoption and service models.
To know more about the market opportunities by region and country, click here to
Buy The Complete Report
Technological Advancements Accelerating Adoption
Expanding Research and Clinical Applications
High Costs Of Instruments and Reagents
Complex Data Analysis Requirements
Request Free Customization of this report to help us to meet your business objectives.
The global single cell omics market is experiencing platform consolidation and technology differentiation due to the demand for multimodal and spatial data, resulting in patent settlements, strategic acquisitions, and commercial partnerships. The 10x Genomics litigation settlement with Bio Rad, BICO Group’s acquisitions of Cytena and Biosero, and PerkinElmer’s partnership with Honeycomb to commercialize single cell RNA solutions are examples.
Top Player’s Company Profile
Recent Developments in the Single-cell Omics Market
SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Correlates, and Analyses the Data collected by means of Primary Exploratory Research backed by robust Secondary Desk research.
As per SkyQuest analysis, the global single-cell omics industry is primarily driven by declining per-sample and per-cell costs that enable large-cohort studies and drive adoption in academia and industry. Advances in AI, computational analytics and spatial multi-omics accelerate further adoption by improving biomarker discovery and multi-modal integration. However, the growth is restricted by the complex data analysis requirements which pose a bottleneck for organizations without bioinformatics expertise and infrastructure. North America remains the dominant region, fuelled by clustered research centers, commercial ecosystems and translational pathways. Single-cell transcriptomics dominates the technology mix as mature protocols and widespread reagent availability position it as the primary discovery engine for target and biomarker identification.
| Report Metric | Details |
|---|---|
| Market size value in 2024 | USD 4.82 Billion |
| Market size value in 2033 | USD 18.85 Billion |
| Growth Rate | 16.32% |
| Base year | 2024 |
| Forecast period | (2026-2033) |
| Forecast Unit (Value) | USD Billion |
| Segments covered |
|
| Regions covered | North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA) |
| Companies covered |
|
| Customization scope | Free report customization with purchase. Customization includes:-
|
To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.
Table Of Content
Executive Summary
Market overview
Parent Market Analysis
Market overview
Market size
KEY MARKET INSIGHTS
COVID IMPACT
MARKET DYNAMICS & OUTLOOK
Market Size by Region
KEY COMPANY PROFILES
Methodology
For the Single-cell Omics Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:
1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.
2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Single-cell Omics Market.
3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.
4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.
Analyst Support
Customization Options
With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Single-cell Omics Market:
Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.
Regional Analysis: Further analysis of the Single-cell Omics Market for additional countries.
Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.
Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.
Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.
Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.
Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.
Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.
REQUEST FOR SAMPLE
REQUEST FREE CUSTOMIZATION
Global Single-Cell Omics Market size was valued at USD 4.82 Billion in 2024 and is poised to grow from USD 5.61 Billion in 2025 to USD 18.85 Billion by 2033, growing at a CAGR of 16.32% during the forecast period (2026-2033).
Competitive landscape in global single cell omics is marked by platform consolidation and technology differentiation driven by demand for multimodal and spatial data, prompting patent settlements, strategic acquisitions, and commercial partnerships. Examples include 10x Genomics litigation settlement with Bio Rad, BICO Group acquisitions of Cytena and Biosero, and PerkinElmer’s partnership with Honeycomb to commercialize single cell RNA solutions. '10x Genomics', 'Illumina Inc.', 'Thermo Fisher Scientific', 'Fluidigm Corporation', 'Bio-Rad Laboratories', 'Becton Dickinson', 'Miltenyi Biotec', 'Parse Biosciences', 'Vizgen Inc.', 'NanoString Technologies', 'Akoya Biosciences', 'Singlera Genomics', 'Mission Bio', 'Cellenics', 'Curio Bioscience', 'Scale Biosciences', 'Honeycomb Biotechnologies', 'Singular Genomics', 'Aspect Biosystems', 'Berry Genomics'
Rapid improvements in single-cell sequencing platforms, microfluidics, and imaging technologies have increased the accessibility and sensitivity of single-cell omics workflows, enabling researchers to profile individual cells with greater confidence. These technological advancements reduce technical barriers, improve sample throughput, and expand the range of biological questions addressable, thereby encouraging wider adoption across academic, clinical, and industrial settings. As instrument capabilities and reagent quality continue to evolve, stakeholders are more likely to invest in single-cell solutions, fostering market expansion through increased demand for systems, consumables, and services.
Integrated Multi Omics Adoption: Adoption of integrated multi omics workflows is driving demand for platforms that combine single cell genomics, transcriptomics, proteomics and epigenomics to deliver biological insights. Researchers and biopharma prioritize solutions that reduce sample loss, harmonize protocols and enable cross modal data interpretation. This trend encourages vendors to develop interoperable instruments, standardized reagents and models that simplify complex experimental design. Increased collaboration between technology developers and application scientists accelerates translational research and supports uptake in drug discovery, diagnostics and precision medicine initiatives.
Why does North America Dominate the Global Single-cell Omics Market? |@12
Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.
Feedback From Our Clients
USA (+1) 351-333-4748
